Standout Papers

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial 2002 2026 2010 2018 3.1k
  1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (2002)
    Stephen B. Hanauer, Brian G. Feagan et al. The Lancet
  2. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2005)
    Paul Rutgeerts, William J. Sandborn et al. New England Journal of Medicine
  3. Ulcerative colitis (2016)
    Ryan C. Ungaro, Saurabh Mehandru et al. The Lancet
  4. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (2010)
    Jean‐Frédéric Colombel, William J. Sandborn et al. New England Journal of Medicine
  5. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2013)
    Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine
  6. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (2013)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  7. Crohn's disease (2016)
    Joana Torres, Saurabh Mehandru et al. The Lancet
  8. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD (2021)
    Dan Turner, Amanda Ricciuto et al. Gastroenterology
  9. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management (2010)
    Axel Dignaß, Gert Van Assche et al. Journal of Crohn s and Colitis
  10. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2011)
    William J. Sandborn, Gert Van Assche et al. Gastroenterology
  11. CARD15/NOD2 Mutational Analysis and Genotype-Phenotype Correlation in 612 Patients with Inflammatory Bowel Disease (2002)
    Suzanne Lesage, Habib Zouali et al. The American Journal of Human Genetics
  12. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab (2007)
    William J. Sandborn, Paul Rutgeerts et al. Annals of Internal Medicine
  13. The Natural History of Adult Crohn's Disease in Population-Based Cohorts (2009)
    Laurent Peyrin‐Biroulet, Edward V. Loftus et al. The American Journal of Gastroenterology
  14. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease (2004)
    Paul Rutgeerts, Brian G. Feagan et al. Gastroenterology
  15. Mapping of a susceptibility locus for Crohn's disease on chromosome 16 (1996)
    Jean‐Pierre Hugot, Pierre Laurent‐Puig et al. Nature
  16. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial (2016)
    Julián Panés, Damián García‐Olmo et al. The Lancet
  17. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  18. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis (2011)
    Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology
  19. Natalizumab Induction and Maintenance Therapy for Crohn's Disease (2005)
    William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine
  20. The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients (2003)
    Jean‐Frédéric Colombel, Edward V. Loftus et al. Gastroenterology
  21. The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016)
    Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut
  22. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  23. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (2014)
    Bruce E. Sands, Brian G. Feagan et al. Gastroenterology
  24. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management (2016)
    Giulia Roda, Bindia Jharap et al. Clinical and Translational Gastroenterology
  25. Geographical variability and environmental risk factors in inflammatory bowel disease (2013)
    Siew C. Ng, Çharles N. Bernstein et al. Gut
  26. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020)
    Erica J. Brenner, Ryan C. Ungaro et al. Gastroenterology
  27. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis (2018)
    Sudarshan Paramsothy, Shaun Nielsen et al. Gastroenterology
  28. Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease (2016)
    Gautier Hoarau, Pranab K. Mukherjee et al. mBio
  29. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions (2015)
    Laurent Peyrin‐Biroulet, Julián Panés et al. Clinical Gastroenterology and Hepatology
  30. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017)
    Julián Panés, William J. Sandborn et al. Gut
  31. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease (2023)
    Edward V. Loftus, Julián Panés et al. New England Journal of Medicine
  32. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists (2021)
    Manasi Agrawal, Elizabeth A. Spencer et al. Gastroenterology
  33. Multiomics to elucidate inflammatory bowel disease risk factors and pathways (2022)
    Manasi Agrawal, Kristine H. Allin et al. Nature Reviews Gastroenterology & Hepatology
  34. Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study (2023)
    Adam S. Faye, Kristine H. Allin et al. Gut

Immediate Impact

6 by Nobel laureates 27 from Science/Nature 238 standout
Sub-graph 1 of 10

Citing Papers

Synergy and oxygen adaptation for development of next-generation probiotics
2023 StandoutNature
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2023 Standout
251 intermediate papers

Works of Jean‐Frédéric Colombel being referenced

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011 Standout
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
and 105 more

Author Peers

Author Last Decade Papers Cites
Jean‐Frédéric Colombel 41043 31226 15887 711 57.3k
Séverine Vermeire 34605 25404 12297 1.2k 53.6k
Paul Rutgeerts 47645 36937 16107 554 63.7k
Laurent Peyrin‐Biroulet 32828 24374 12865 1.1k 47.8k
Brian G. Feagan 40888 31094 14136 747 52.5k
Silvio Danese 28863 20178 12757 1.3k 48.6k
Stefan Schreiber 25944 17883 10133 870 50.1k
Geert D’Haens 30399 23520 11890 897 41.6k
Bruce E. Sands 27560 20316 10502 579 38.2k
Remo Panaccione 25603 18908 9789 684 35.4k
Gert Van Assche 26295 20158 10425 445 35.8k

All Works

Loading papers...

Rankless by CCL
2026